ecNumber*3.4.21.20#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*36502#!ecNumber*3.4.21.20#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*36505#!ecNumber*3.4.21.20#specificActivity*-999#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*36517#!ecNumber*3.4.21.20#specificActivity*-999#specificActivityMaximum*#commentary*development of sensitive cathepsin G fluorogenic substrate using combinatorial chemistry methods, overview#organism*Homo sapiens#literature*683071#!ecNumber*3.4.21.20#specificActivity*-999#specificActivityMaximum*#commentary*15% cathepsin G acitivity among total proteolytic activity of fecal supernatants, in patients with ulcerative colitits; 7% cathepsin G acitivity among total proteolytic activity of fecal supernatants, in healthy patients#organism*Homo sapiens#literature*707047#!ecNumber*3.4.21.20#specificActivity*2.02#specificActivityMaximum*#commentary*healthy subjects#organism*Homo sapiens#literature*707047#!ecNumber*3.4.21.20#specificActivity*3.2#specificActivityMaximum*#commentary*#organism*Oryctolagus cuniculus#literature*36520#!ecNumber*3.4.21.20#specificActivity*6.51#specificActivityMaximum*#commentary*purified enzyme#organism*Canis lupus familiaris#literature*650266#!ecNumber*3.4.21.20#specificActivity*16.14#specificActivityMaximum*#commentary*patients with ulcerative colitis and specific Cat-G inhibitor#organism*Homo sapiens#literature*707047#!ecNumber*3.4.21.20#specificActivity*28.34#specificActivityMaximum*#commentary*patients with ulcerative colitis#organism*Homo sapiens#literature*707047#!ecNumber*3.4.21.20#specificActivity*148#specificActivityMaximum*#commentary*#organism*Homo sapiens#literature*653984#